Quality standards in respiratory real-life effectiveness research: The REal Life EVidence AssessmeNt Tool (RELEVANT): Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force
Quality standards in respiratory real-life effectiveness research: The REal Life EVidence AssessmeNt Tool (RELEVANT): Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force
Introduction: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. Methods: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. Results: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. Conclusions: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice.
Asthma, Comparative effectiveness, Database, Observational studies, Quality standards
Roche, Nicolas
59e3804d-1f4f-48f4-abbc-37c44279b126
Campbell, Jonathan D.
a17142a5-833b-4da0-9b3d-b55ef9e77f03
Krishnan, Jerry A.
738f057a-5ab2-4a6a-b4aa-bba676d37428
Brusselle, Guy
7b8ee2aa-06d6-437c-8591-b09be09fed7b
Chisholm, Alison
b9c6e5d9-a4f3-4d05-aaa4-a1435fdc7771
Bjermer, Leif
b1880328-5814-4334-b922-4ed3332b7bae
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Van Ganse, Eric
1b5ed09b-c6fd-49df-a284-3cda931a37d7
Van Den Berge, Maarten
998f7d7f-9878-4bf9-8734-dcfe65aff04e
Christoff, George
b2c91d5e-8c0e-49f7-9ca7-ac9635eae33b
Quint, Jennifer
22800655-8987-4464-8385-7f08860c92f9
Papadopoulos, Nikolaos G.
acf133b9-9a22-4637-a7f3-d67f509d9353
Price, David
4dee6753-83c4-4b65-aa9d-f4e915018b57
27 March 2019
Roche, Nicolas
59e3804d-1f4f-48f4-abbc-37c44279b126
Campbell, Jonathan D.
a17142a5-833b-4da0-9b3d-b55ef9e77f03
Krishnan, Jerry A.
738f057a-5ab2-4a6a-b4aa-bba676d37428
Brusselle, Guy
7b8ee2aa-06d6-437c-8591-b09be09fed7b
Chisholm, Alison
b9c6e5d9-a4f3-4d05-aaa4-a1435fdc7771
Bjermer, Leif
b1880328-5814-4334-b922-4ed3332b7bae
Thomas, Mike
997c78e0-3849-4ce8-b1bc-86ebbdee3953
Van Ganse, Eric
1b5ed09b-c6fd-49df-a284-3cda931a37d7
Van Den Berge, Maarten
998f7d7f-9878-4bf9-8734-dcfe65aff04e
Christoff, George
b2c91d5e-8c0e-49f7-9ca7-ac9635eae33b
Quint, Jennifer
22800655-8987-4464-8385-7f08860c92f9
Papadopoulos, Nikolaos G.
acf133b9-9a22-4637-a7f3-d67f509d9353
Price, David
4dee6753-83c4-4b65-aa9d-f4e915018b57
Roche, Nicolas, Campbell, Jonathan D., Krishnan, Jerry A., Brusselle, Guy, Chisholm, Alison, Bjermer, Leif, Thomas, Mike, Van Ganse, Eric, Van Den Berge, Maarten, Christoff, George, Quint, Jennifer, Papadopoulos, Nikolaos G. and Price, David
(2019)
Quality standards in respiratory real-life effectiveness research: The REal Life EVidence AssessmeNt Tool (RELEVANT): Report from the Respiratory Effectiveness Group - European Academy of Allergy and Clinical Immunology Task Force.
Clinical and Translational Allergy, 9 (1), [20].
(doi:10.1186/s13601-019-0255-x).
Abstract
Introduction: A Task Force was commissioned jointly by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a quality assessment tool for real-life observational research to identify high-quality real-life asthma studies that could be considered within future guideline development. Methods: The resulting REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved through an extensive analysis of existing initiatives in this area. The first version was piloted among 9 raters across 6 articles; the revised, interim, version underwent extensive testing by 22 reviewers from the EAACI membership and REG collaborator group, leading to further revisions and tool finalisation. RELEVANT was validated through an analysis of real-life effectiveness studies identified via systematic review of Medline and Embase databases and relating to topics for which real-life studies may offer valuable evidence complementary to that from randomised controlled trials. The topics were selected through a vote among Task Force members and related to the influence of adherence, smoking, inhaler device and particle size on asthma treatment effectiveness. Results: Although highlighting a general lack of high-quality real-life effectiveness observational research on these clinically important topics, the analysis provided insights into how identified observational studies might inform asthma guidelines developers and clinicians. Overall, RELEVANT appeared reliable and easy to use by expert reviewers. Conclusions: Using such quality appraisal tools is mandatory to assess whether specific observational real-life effectiveness studies can be used to inform guideline development and/or decision-making in clinical practice.
Text
s13601-019-0255-x
- Version of Record
More information
Accepted/In Press date: 31 January 2019
Published date: 27 March 2019
Keywords:
Asthma, Comparative effectiveness, Database, Observational studies, Quality standards
Identifiers
Local EPrints ID: 430073
URI: http://eprints.soton.ac.uk/id/eprint/430073
PURE UUID: 63a2abd3-8144-4738-b5ed-32839fca4d00
Catalogue record
Date deposited: 11 Apr 2019 16:30
Last modified: 17 Mar 2024 12:24
Export record
Altmetrics
Contributors
Author:
Nicolas Roche
Author:
Jonathan D. Campbell
Author:
Jerry A. Krishnan
Author:
Guy Brusselle
Author:
Alison Chisholm
Author:
Leif Bjermer
Author:
Eric Van Ganse
Author:
Maarten Van Den Berge
Author:
George Christoff
Author:
Jennifer Quint
Author:
Nikolaos G. Papadopoulos
Author:
David Price
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics